Physician profile
Eric A Benning
NPI 1932196755
$2,568.94
in general payments reported to CMS, 2019-2025
27 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $191 · 2021: $486 · 2022: $580 · 2023: $326 · 2024: $390 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $598.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $388.40 | 2021-2025 | Trelegy Ellipta, Shingrix, Pediarix |
| Novo Nordisk INC | $199.31 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $184.77 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $165.34 | 2019-2022 | |
| Abbott Laboratories | $139.97 | 2021-2025 | Freestyle Libre 3, Eterna |
| Vanda Pharmaceuticals INC. | $137.41 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.14 | 2019-2024 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $104.98 | 2024 | |
| Redhill Biopharma INC. | $84.80 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $71.81 | 2022-2025 | Capvaxive, Gardasil 9, Lagevrio |
| Astrazeneca Pharmaceuticals Lp | $63.52 | 2023-2024 | Farxiga, Airsupra, Fasenra |
| Pfizer INC. | $36.32 | 2023-2024 | |
| Gilead Sciences, INC. | $32.94 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $23.14 | 2024 | Uptravi, Opsumit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.07 | 2021 | |
| Shield Therapeutics INC | $22.49 | 2022 | |
| Amarin Pharma, INC. | $21.69 | 2019 | |
| Eisai INC. | $20.89 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.46 | 2022 | |
| Boston Scientific Corporation | $15.20 | 2019 | |
| Exact Sciences Corporation | $14.85 | 2025 | The Cologuard Plus Collection Kit |
| Emd Serono, INC. | $14.59 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.48 | 2022 | |
| Echosens North America, INC. | $13.78 | 2025 | Fibroscan |
| Kowa Pharmaceuticals America, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Benning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.